Renal cell carcinoma

Common Name(s)

Renal cell carcinoma

Renal cell carcinoma (RCC) is one of the most common types of kidney cancers seen in adults. RCC occurs more often in men between the ages of 50 to 70. The kidneys help get rid of waste in the body. There are small tubes in the kidneys that help filter waste from the blood and help make urine. RCC occurs when cells start growing uncontrollably in the lining of these small tubes. Symptoms may not appear in the early stages of renal cell carcinoma, which is why renal cell carcinoma is normally advanced when found. Later symptoms may include blood in urine, a lump in the abdomen, weight loss, anemia, and loss of appetite. If untreated, it may spread to the lymph nodes, lungs, liver, adrenal glands, brain, or bones.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma" returned 4389 free, full-text research articles on human participants. First 3 results:

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
 

Author(s): Anna Buda-Nowak, Jakub Kucharz, Paulina Dumnicka, Marek Kuzniewski, Roman Maria Herman, Aneta L Zygulska, Beata Kusnierz-Cabala

Journal: Med. Oncol.. 2017 Apr;34(4):68.

 

Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation ...

Last Updated: 26 Mar 2017

Go To URL
Case report of primary renal pelvis squamous cell carcinoma coexisting with long-standing calculi in left kidney on 18F-FDG PET/CT.
 

Author(s): Shengming Deng, Bin Zhang, Ying Huang, Jihui Li, Shibiao Sang, Wei Zhang

Journal: Medicine (Baltimore). 2017 Mar;96(11):e6341.

 

Primary renal pelvis squamous cell carcinoma (SCC) is an extremely rare neoplasm. In many patients, the SCC was associated with renal calculi.

Last Updated: 15 Mar 2017

Go To URL
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
 

Author(s): Sung Han Kim, Sohee Kim, Byung-Ho Nam, Sang Eun Lee, Choung-Soo Kim, Ill Young Seo, Tae Nam Kim, Sung-Hoo Hong, Tae Gyun Kwon, Seong Il Seo, Kwan Joong Joo, Kanghyon Song, Cheol Kwak, Jinsoo Chung

Journal: Biomed Res Int. 2017 ;2017():9215930.

 

We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib. We investigated 177 patients, including 116 who received sorafenib as first-line therapy, using ...

Last Updated: 8 Mar 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma" returned 530 free, full-text review articles on human participants. First 3 results:

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
 

Author(s): Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson

Journal:

 

In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international ...

Last Updated: 23 Feb 2017

Go To URL
Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis.
 

Author(s): Yuejun Tian, Mei Hong, Suoshi Jing, Xingchen Liu, Hanzhang Wang, Xinping Wang, Dharam Kaushik, Ronald Rodriguez, Zhiping Wang

Journal: Biomed Res Int. 2017 ;2017():9591506.

 

Background. Although numerous studies have shown that plasma fibrinogen is linked to renal cell carcinoma (RCC) risk, the consistency and magnitude of the effect of plasma fibrinogen are unclear. The aim of the study was to explore the association between plasma fibrinogen and RCC ...

Last Updated: 3 Feb 2017

Go To URL
Targeted Therapy for Metastatic Renal Cell Carcinoma.
 

Author(s): Andika Afriansyah, Agus Rizal Ah Hamid, Chaidir A Mochtar, Rainy Umbas

Journal: Acta Med Indones. 2016 Oct;48(4):335-347.

 

In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were developed, including multi-targeted tyrosine kinase inhibitors ...

Last Updated: 1 Feb 2017

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
 

Status: Not yet recruiting

Condition Summary: Renal Cell Carcinoma

 

Last Updated: 26 Apr 2017

Go to URL
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Renal Cell Carcinoma

 

Last Updated: 25 Apr 2017

Go to URL
Molecular Determinants for Therapy Response on Renal Cell Carcinoma
 

Status: Recruiting

Condition Summary: Renal Cell Carcinoma

 

Last Updated: 31 Jul 2014

Go to URL